Cognition Therapeutics Inc. (CGTX) Soars 25.45% on FDA Trial Endorsement

On August 13, 2025, Cognition Therapeutics Inc. (CGTX) experienced a significant surge, rising 25.45% in pre-market trading, driven by positive developments in its Alzheimer's drug trial.

Cognition Therapeutics' stock price soared due to the FDA's endorsement of the Phase 3 trial design for its Alzheimer's drug. This approval is a critical milestone for the company, as it validates the efficacy and safety of its treatment approach, potentially paving the way for future regulatory approvals and market entry.

The positive news from the FDA has bolstered investor confidence in Cognition Therapeutics' prospects, leading to a substantial increase in its stock price. The endorsement underscores the company's commitment to developing innovative treatments for neurodegenerative diseases and highlights the potential of its drug pipeline.